Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
Table 1
Clinical profile of 26 eyes of 25 cases from the Collaborative Choroidal Osteoma Group.
Case .
Age
Gender
Osteoma location
CNV location
Initial vision
Final vision
Initial CFT
6-month CFT
Type of injections
Follow-up (month)
Number of injection
Osteoma longest dimension (disc diameter)
1
34
F
Subfoveal
Juxtafoveal
20/300 (6/90)
20/60 (6/18)
NA
174
Bevacizumab
18
2
3
2
37
M
Posterior pole
Subfoveal with blood
20/25 (6/7.5)
20/20 (6/6)
NA
NA
Bevacizumab
52
8
10
3
43
F
Subfoveal
Subfoveal with blood
20/32 (6/9.5)
20/100 (6/30)
294
197
Ranibizumab
18
1
4
4
8
F
Subfoveal
Subfoveal with blood
CF
20/40 (6/12)
434
NA
Bevacizumab
24
2
7
5
28
M
Subfoveal
Subfoveal with SRF
20/60 (6/18)
20/80 (6/24)
373
252
Bevacizumab
46
3
7
6
13
F
Subfoveal
Subfoveal with blood
20/100 (6/30)
20/50 (6/15)
307
212
Ranibizumab
42
3
5
7
27
M
Superotemporal arcade
Extrafoveal with blood
20/80 (6/24)
20/30 (6/9)
NA
NA
Ranibizumab
18
7
9
8
27
F
Subfoveal
Extrafoveal
20/30 (6/9)
20/20 (6/6)
264
207
Bevacizumab
12
1
4
9
46
F
Subfoveal
Subfoveal with blood
20/300 (6/90)
20/80 (6/24)
244
NA
Bevacizumab
60
8
6
10
37
F
Posterior pole
Peripapillary
20/80 (6/24)
20/20 (6/6)
790
360
Bevacizumab
26
4
1
11
28
F
Posterior pole
Peripapillary
20/400 (6/120)
20/400 (6/120)
Highly elevated serous macular detachment
highly elevated serous macular detachment
Ranibizumab
8
2
4
12
48
F
Subfoveal & juxtafoveal
Subfoveal & juxtafoveal
20/40 (6/12)
20/20 (6/6)
298
306
Ranibizumab number 5, Bevacizumab number 10
35
15
3
13
25
F
Subfoveal
Subfoveal
20/80 (6/24)
20/20 (6/6)
203
166
Ranibizumab
15
1
1
14
33
F
Subfoveal
Subfoveal
(20/67) 6/20
(20/320) 6/95
316
Bevacizumab
24
3
2
15
22
M
Subfoveal
Juxtafoveal
CF 1 m
CF 2 m
NA
675
Bevacizumab
7
3
6
16
41
F
Juxtafoveal
Juxtafoveal
20/200 (6/60)
20/200 (6/60)
427
258
Ranibizumab number 3 Bevacizumab number 1
6
4
3
17
24
M
Extrafoveal
Extrafoveal with blood
20/60 (6/18)
20/30 (6/9)
350
210
Bevacizumab
54
17
2
18
14
M
Subfoveal
Subfoveal with blood
CFNF
CFNF
>1000
>500
Bevacizumab number 4 Ranibizumab number 5
26
9
8
19
35
F
Posterior pole
Peripapillary
20/70 (6/21)
20/40 (6/12)
600
400
Bevacizumab
12
2
7
20
45
M
Subfoveal
Juxtafoveal
20/63 (6/19)
20/32 (6/9.5)
237
222
Bevacizumab
6
2
1.2
21
13
F
Subfoveal
Subfoveal
20/200 (6/60)
20/63 (6/19)
339
249
Bevacizumab
6
2
4
22
20
M
Subfoveal
Juxtafoveal
20/70 (6/21)
20/40 (6/12)
282
171
Bevacizumab
71
1
4
23
22
M
Subfoveal
Subfoveal
20/160 (6/48)
20/250 (6/75)
427
225
Bevacizumab
46
5
4.9
24
11
M
Juxtafoveal
Extrafoveal
20/20 (6/6)
20/20 (6/6)
NA
NA
Bevacizumab
16
3
3.4
25
57
F
Subfoveal
Subfoveal
20/800 (6/240)
20/30 (6/9)
NA
283
Ranibizumab number 3 Bevacizumab number 3
21
6
4
26
25
F
Extrafoveal
Subfoveal
20/300 (6/90)
20/100 (6/30)
360
320
Bevacizumab
12
2
6
= number; CFT = central foveal thickness; SRF = subretinal fluid; F = female; M = male; NA = not available; CF = counting fingers; CFNF = finger counting at near face.
